Mauro Ferrari
Known title: DirectorCIK: 0001506045
Associated companies
Transaction History
| ARWR | ▼ Sell | Open Market | 7,530 | $527K | 12/26/2025 | View on chart |
| ARWR | ▲ Buy | Grant | 7,819 | $0 | 12/16/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 8,750 | $493K | 11/28/2025 | View on chart |
| ARWR | ▲ Buy | Grant | 16,733 | $385K | 12/18/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,147 | $81K | 1/11/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,000 | $39K | 1/11/2024 | View on chart |
| ARWR | ▲ Buy | Grant | 14,987 | $381K | 12/15/2023 | View on chart |
| ARWR | ▲ Buy | Grant | 7,867 | $0 | 1/10/2023 | View on chart |
| ARWR | ▲ Buy | Grant | 6,400 | $0 | 1/7/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 3,400 | $227K | 12/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value
Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value. Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.